Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclacel Pharmaceuti (CYCCP)

Cyclacel Pharmaceuti (CYCCP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cyclacel Pharmaceuti

https://cyclacel.com F: 866-271-3466

Description:

Cyclacel Pharmaceuticals, Inc. was incorporated in the state of Delaware in 1996. It is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. The Company's goal is to develop and commercialize small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. The Company's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Cyclacel's clinical development priorities are focused on sapacitabine, an orally available, cell cycle modulating nucleoside analogue. Sapacitabine is being evaluated in the SEAMLESS Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA) for the front-line treatment of acute myeloid leukemia (AML) in the elderly and in Phase 2 studies for AML, myelodysplastic syndromes (MDS), non-small cell lung cancer (NSCLC) and chronic lymphocytic leukemia. Sapacitabine is also being evaluated in a Phase1/2 study in combination with seliciclib, its second clinical candidate. The Company has ongoing clinical programs with seliciclib in NSCLC and nasopharyngeal cancer (NPC) and once data becomes available and is reviewed, the Company will determine the feasibility of pursuing further development and/or partnering these assets. In addition, the Company markets directly in the United States Xclair Cream for radiation dermatitis and Numoisyn Liquid and Numoisyn Lozenges for xerostomia.

Key Statistics

Overview:

Annual Sales, $ 420 K
Annual Net Income, $ -22,555 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -1,957 K
Short Volume Ratio 1.00

Growth:

1-Year Return -56.47%
3-Year Return -45.00%
5-Year Return 21.24%

Per-Share Information:

Next Earnings Date N/A
Next Ex-Dividends Date 12/31/14
Dividend Payable Date 01/15/15
Dividend Payout Ratio 0.00%

CYCCP Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % -5,418.10%
Debt/Equity 0.06
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share N/A
Interest Coverage N/A

CYCCP Dividends

Date Value
07/15/15 $0.1500
04/15/15 $0.1500
12/31/14 $0.1500
09/29/14 $0.1500
06/27/14 $0.1500
04/15/14 $0.1500
01/15/14 $0.1500
10/17/13 $0.1500
07/18/13 $0.1500
04/17/13 $0.1500
01/17/13 $0.1500
04/19/11 $0.1500
01/19/11 $0.1500
01/14/09 $0.1500
10/16/08 $0.1500
07/16/08 $0.1500
04/16/08 $0.1500
01/16/08 $0.1500
10/17/07 $0.1500
07/18/07 $0.1500
04/18/07 $0.1500
01/18/07 $0.1500
10/19/06 $0.1500
07/20/06 $0.1500
04/26/06 $0.1500
01/18/06 $0.1500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar